Aurion Biotech
Focus: Aurion Biotech is a public biotechnology company founded in 2015, focused exclusively on ocular transplant therapies with a pipeline of allogeneic corneal endothelial cell products for corneal edema. The company operates as a specialized biotech player with a narrowly focused therapeutic area.
Profile data last refreshed 2h ago · AI intelligence enriched 5d ago
Funding Stage
PUBLIC
Open Jobs
8-2 this month
Stable — net -2 jobs in 30d
3 added, 5 removed. Backfill posture.
Should You Work at Aurion Biotech?
AI assessmentBest for cell therapy specialists and clinical ops professionals seeking meaningful ownership in a focused, high-risk biotech with a near-term Phase 3 catalyst; unsuitable for those prioritizing financial stability or broad career optionality.
Why Work Here
- Leadership role in an emerging cell therapy modality with 5 active programs across Phase 1–3 and recent Phase 3 dosing initiation (April 2026), offering rare early-stage exposure to regenerative medicine.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
HCEC-1
Corneal EdemaClinical Trials (1)
NCT05309135A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction
Phase 1Help build intelligence for Aurion Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.